ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  melphalan
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR104761, NCI-2015-01729, 2014-002272-88, 54767414MMY3007, NCT02195479
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHP-OCM-301, NCI-2016-00242, NCT02678572
Lenalidomide, High-Dose Melphalan, and Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0290, NCI-2010-01423, NCT01142232
Umbilical Cord Blood-Derived Natural Killer Cells, High Dose Chemotherapy, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCI-2014-00541, RV-MM-PI-0691, NCT01729091
Carfilzomib and Melphalan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1185, NCI-2013-00550, NCT01842308
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients with High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 75
Trial IDs: 2241.00, NCI-2009-01334, NCT01008462
Busulfan, Melphalan, Fludarabine Phosphate, and T Cell-Depleted Donor Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients with Relapsed or High-Risk Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 to 69
Trial IDs: 10-051, NCI-2010-01306, NCT01131169
High-Dose Melphalan and Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: MT2003-13, NCI-2010-01413, NCT00293306, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00177047
Rituximab and Ibritumomab Tiuxetan in Treating Patients With Stage II-III Multiple Myeloma
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 7306, NCI-2010-02131, NCT01207765
Autologous Stem Cell Transplant Followed by Maintenance Therapy in Treating Elderly Patients with Multiple Myeloma
Status: Active
Phase: Phase II
Type: Treatment
Age: 65 to 85
Trial IDs: 201208775, NCI-2013-00883, 10120146, NCT01849783
Granix to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Transplantation
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201405057, NCI-2014-00738, 14-x003, NCT02112045
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: BMTCTN1302, NCI-2015-01829, U01HL069294-05, NCT02440464
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan before Stem Cell Transplant in Treating Patients with Refractory or Relapsed Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 2014-0516, NCI-2015-01308, NCT02506959
Depleted Immune Suppressor Stem Cell Transplant in Enhancing Immune Response to Vaccines in Patients with Multiple Myeloma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: WINSHIP2905-15, NCI-2015-00743, IRB00079982, NCT02700841
Blinatumomab and T Cell Depleted Donor Blood Cell Transplant in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancy after a Previous Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: REF2HCT, NCI-2016-00812, NCT02790515
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 75 and under
Trial IDs: 2016LS132, NCI-2017-01037, NCT03125642
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for High-Risk Stage I or II Multiple Myeloma
Status: Temporarily closed
Phase: Phase I
Type: Treatment
Age: 70 and under
Trial IDs: 09171, NCI-2010-01610, 09171/118430, 117041, 118430, NCT01163357
Regulatory T-cell Depletion before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase I
Type: Supportive care, Treatment
Age: 21 to 70
Trial IDs: 10-551-B, NCI-2015-01660, NCT01526096
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR103015, NCI-2014-02217, 2013-003491-12, 54767414MMY1001, NCT01998971
Ipilimumab before Isolated Limb Infusion with Melphalan in Treating Patients with Stage IIIB-IV In-Transit Extremity Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 19
Trial IDs: Pro00046479, NCI-2014-01416, NCT02115243
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients with Relapsed High-Risk Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 11097, NCI-2015-01065, HEM-14099-LM, NCT02504359
Engineered Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 60
Trial IDs: 2014-0738, NCI-2016-01915, NCT02960646
Partially HLA-Mismatched Related Donor Stem Cell Transplant Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection in Treating Patients with Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-1237, NCI-2016-01572, NCT02880293
Start Over